Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance

Tivantinib, also known as ARQ-197, is a potent non-ATP competitive selective c-Met inhibitor currently under phase 3 clinical trial evaluation for liver and lung cancers. In this study, we explored factors that may lead to tivantinib resistance, especially in regards to its interaction with ATP-bind...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhuo-Xun, Yang, Yuqi, Teng, Qiu-Xu, Wang, Jing-Quan, Lei, Zi-Ning, Wang, Jing-Qiu, Lusvarghi, Sabrina, Ambudkar, Suresh V., Yang, Dong-Hua, Chen, Zhe-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017082/
https://www.ncbi.nlm.nih.gov/pubmed/31940916
http://dx.doi.org/10.3390/cancers12010186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017082/
https://www.ncbi.nlm.nih.gov/pubmed/31940916
http://dx.doi.org/10.3390/cancers12010186

Ejemplares similares